Page 50

136 STAT. 1866 PUBLIC LAW 117–169—AUG. 16, 2022 a drug or biological are less than, subject to subpara- graph (B), $100; or ‘‘(ii) that is a vaccine described in subparagraph (A) or (B) of section 1861(s)(10). ‘‘(B) INCREASE.—The dollar amount applied under subparagraph (A)(i)— ‘‘(i) for 2024, shall be the dollar amount specified under such subparagraph for 2023, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year; and ‘‘(ii) for a subsequent year, shall be the dollar amount specified in this clause (or clause (i)) for the previous year (without application of subparagraph (C)), increased by the percentage increase in the con- sumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year. ‘‘(C) ROUNDING.—Any dollar amount determined under subparagraph (B) that is not a multiple of $10 shall be rounded to the nearest multiple of $10. ‘‘(3) REBATE AMOUNT.— ‘‘(A) IN GENERAL.—For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraphs (B) and (G) and para- graph (4), the estimated amount equal to the product of— ‘‘(i) the total number of units determined under subparagraph (B) for the billing and payment code of such drug; and ‘‘(ii) the amount (if any) by which— ‘‘(I) the amount equal to— ‘‘(aa) in the case of a part B rebatable drug described in paragraph (1)(B) of sub- section (b), 106 percent of the amount deter- mined under paragraph (4) of such section for such drug during the calendar quarter; or ‘‘(bb) in the case of a part B rebatable drug described in paragraph (1)(C) of such subsection, the payment amount under such paragraph for such drug during the calendar quarter; exceeds ‘‘(II) the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter. ‘‘(B) TOTAL NUMBER OF UNITS.—For purposes of subparagraph (A)(i), the total number of units for the billing and payment code with respect to a part B rebatable drug furnished during a calendar quarter described in subparagraph (A) is equal to— ‘‘(i) the number of units for the billing and payment code of such drug furnished during such calendar quarter, minus Estimate. Time periods. Time periods. VerDate Sep 11 2014 13:57 Oct 25, 2022 Jkt 029139 PO 00169 Frm 00050 Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL169.117 PUBL169 jmbennett on LAP3P8D0R2PROD with Publaw